Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA receptor encephalitis (ANRE), a rare brain disorder that comes with severe ...

See, e.g., Amgen Inc. v. Sanofi, 872 F.3d 1367 (Fed. Cir. 2017). If possible, including at least one 3D structure of an antibody of interest has been found to be a good idea. In Abbvie Deutschland v.

UPPSALA, Sweden-- (BUSINESS WIRE)-- Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers today announced the introduction of ...

Background: CANOPY (NCT06039449) is a Phase 3 study to evaluate the efficacy and safety of VYD222 for prevention of COVID-19. VYD222 is a fully human IgG1 mAb demonstrating in vitro neutralizing ...

However, there is still a need to develop an anti-CTLA-4 antibody with further improved safety and efficacy profile. KD6001, a novel fully human anti-CTLA4 IgG1 monoclonal antibody that exhibits ...

The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone in the drug development process.Ruxoprubart is an ...

The blood-brain barrier blocks the entry of antibodies into the brain. This limits the potential use of antibody therapeutics to treat brain diseases, such as brain tumors. Elsewhere in the body ...

The structure of the teleost Immunoglobulin M core provides insights on polymeric antibody evolution, assembly, and function. Nature Communications, 2023; 14 (1) DOI: 10.1038/s41467-023-43240-z ...

Fish IgM structure sheds light on antibody evolution, study finds Peer-Reviewed Publication Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign ...

Izadi et al. reengineered eight high affinity and non-neutralizing SARS-CoV-2 antibodies to use an IgG3 structure as opposed to an IgG1.